vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($221.4M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 0.2%, a 13.1% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (6.7% vs -1.8%). Over the past eight quarters, UNIVERSAL TECHNICAL INSTITUTE INC's revenue compounded faster (11.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
AMPH vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $221.4M |
| Net Profit | $24.4M | $433.0K |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 0.2% |
| Net Margin | 13.3% | 0.2% |
| Revenue YoY | -1.8% | 6.7% |
| Net Profit YoY | -35.7% | -60.5% |
| EPS (diluted) | $0.51 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $221.4M | ||
| Q4 25 | $183.1M | $220.8M | ||
| Q3 25 | $191.8M | $222.4M | ||
| Q2 25 | $174.4M | $204.3M | ||
| Q1 25 | $170.5M | $207.4M | ||
| Q4 24 | $186.5M | $201.4M | ||
| Q3 24 | $191.2M | $196.4M | ||
| Q2 24 | $182.4M | $177.5M |
| Q1 26 | — | $433.0K | ||
| Q4 25 | $24.4M | $12.8M | ||
| Q3 25 | $17.4M | $18.8M | ||
| Q2 25 | $31.0M | $10.7M | ||
| Q1 25 | $25.3M | $11.4M | ||
| Q4 24 | $38.0M | $22.2M | ||
| Q3 24 | $40.4M | $18.8M | ||
| Q2 24 | $37.9M | $5.0M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 19.4% | 7.1% | ||
| Q3 25 | 13.2% | 11.2% | ||
| Q2 25 | 24.2% | 6.9% | ||
| Q1 25 | 21.9% | 8.1% | ||
| Q4 24 | 24.2% | 13.6% | ||
| Q3 24 | 29.8% | 13.3% | ||
| Q2 24 | 30.3% | 4.2% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 13.3% | 5.8% | ||
| Q3 25 | 9.0% | 8.4% | ||
| Q2 25 | 17.8% | 5.2% | ||
| Q1 25 | 14.8% | 5.5% | ||
| Q4 24 | 20.4% | 11.0% | ||
| Q3 24 | 21.1% | 9.6% | ||
| Q2 24 | 20.8% | 2.8% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $0.51 | $0.23 | ||
| Q3 25 | $0.37 | $0.33 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.21 | ||
| Q4 24 | $0.74 | $0.40 | ||
| Q3 24 | $0.78 | $0.35 | ||
| Q2 24 | $0.73 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $162.0M |
| Total DebtLower is stronger | $608.7M | $127.8M |
| Stockholders' EquityBook value | $788.8M | $339.9M |
| Total Assets | $1.6B | $852.2M |
| Debt / EquityLower = less leverage | 0.77× | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $162.0M | ||
| Q4 25 | $282.8M | $162.8M | ||
| Q3 25 | $276.2M | $169.1M | ||
| Q2 25 | $231.8M | $70.7M | ||
| Q1 25 | $236.9M | $96.0M | ||
| Q4 24 | $221.6M | $172.0M | ||
| Q3 24 | $250.5M | $161.9M | ||
| Q2 24 | $217.8M | $115.5M |
| Q1 26 | — | $127.8M | ||
| Q4 25 | $608.7M | $101.4M | ||
| Q3 25 | $608.6M | $87.1M | ||
| Q2 25 | $607.7M | $73.8M | ||
| Q1 25 | $603.9M | $94.4M | ||
| Q4 24 | $601.6M | $120.1M | ||
| Q3 24 | $596.4M | $125.7M | ||
| Q2 24 | $586.9M | $137.3M |
| Q1 26 | — | $339.9M | ||
| Q4 25 | $788.8M | $335.9M | ||
| Q3 25 | $776.7M | $328.1M | ||
| Q2 25 | $757.5M | $306.8M | ||
| Q1 25 | $751.3M | $293.9M | ||
| Q4 24 | $732.3M | $280.0M | ||
| Q3 24 | $727.7M | $260.2M | ||
| Q2 24 | $713.3M | $239.4M |
| Q1 26 | — | $852.2M | ||
| Q4 25 | $1.6B | $834.0M | ||
| Q3 25 | $1.7B | $826.1M | ||
| Q2 25 | $1.6B | $740.8M | ||
| Q1 25 | $1.6B | $720.4M | ||
| Q4 24 | $1.6B | $753.8M | ||
| Q3 24 | $1.5B | $744.6M | ||
| Q2 24 | $1.5B | $706.0M |
| Q1 26 | — | 0.38× | ||
| Q4 25 | 0.77× | 0.30× | ||
| Q3 25 | 0.78× | 0.27× | ||
| Q2 25 | 0.80× | 0.24× | ||
| Q1 25 | 0.80× | 0.32× | ||
| Q4 24 | 0.82× | 0.43× | ||
| Q3 24 | 0.82× | 0.48× | ||
| Q2 24 | 0.82× | 0.57× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $7.1M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 16.33× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $7.1M | ||
| Q4 25 | $32.9M | $3.1M | ||
| Q3 25 | $52.6M | $57.1M | ||
| Q2 25 | $35.6M | $18.1M | ||
| Q1 25 | $35.1M | $-789.0K | ||
| Q4 24 | $29.0M | $23.0M | ||
| Q3 24 | $60.0M | $67.5M | ||
| Q2 24 | $69.1M | $10.0M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $-19.2M | ||
| Q3 25 | $47.2M | $40.6M | ||
| Q2 25 | $25.0M | $6.8M | ||
| Q1 25 | $24.4M | $-11.7M | ||
| Q4 24 | $16.6M | $19.6M | ||
| Q3 24 | $46.2M | $60.0M | ||
| Q2 24 | $63.1M | $3.0M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | -8.7% | ||
| Q3 25 | 24.6% | 18.3% | ||
| Q2 25 | 14.3% | 3.4% | ||
| Q1 25 | 14.3% | -5.7% | ||
| Q4 24 | 8.9% | 9.7% | ||
| Q3 24 | 24.1% | 30.6% | ||
| Q2 24 | 34.6% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 10.1% | ||
| Q3 25 | 2.8% | 7.4% | ||
| Q2 25 | 6.1% | 5.5% | ||
| Q1 25 | 6.3% | 5.3% | ||
| Q4 24 | 6.7% | 1.7% | ||
| Q3 24 | 7.2% | 3.8% | ||
| Q2 24 | 3.3% | 4.0% |
| Q1 26 | — | 16.33× | ||
| Q4 25 | 1.35× | 0.24× | ||
| Q3 25 | 3.03× | 3.04× | ||
| Q2 25 | 1.15× | 1.69× | ||
| Q1 25 | 1.39× | -0.07× | ||
| Q4 24 | 0.76× | 1.04× | ||
| Q3 24 | 1.48× | 3.58× | ||
| Q2 24 | 1.82× | 2.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
UTI
Segment breakdown not available.
